Chemistry:3-Methylbutyrfentanyl

From HandWiki
Short description: Opioid analgesic
3-Methylbutyrfentanyl
3-Methylbutyrfentanyl structure.png
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC24H32N2O
Molar mass364.533 g·mol−1
3D model (JSmol)

3-Methylbutyrfentanyl (3-MBF) is an opioid analgesic that is an analog of butyrfentanyl.[2][3][4][5]

Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear.[6]

See also

References

  1. Drug Enforcement Administration, Department of Justice (February 2018). "Schedules of Controlled Substances:Temporary Placement of Fentanyl-Related Substances in Schedule I. Temporary amendment; temporary scheduling order". Federal Register 83 (25): 5188–92. PMID 29932611. 
  2. "Studies on 1-(2-phenethyl)-4-(N -propionylanilino)piperidine (fentanyl) and its related compounds. VI. Structure-analgesic activity relationship for fentanyl, methyl-substituted fentanyls and other analogues". Forensic Toxicology 26 (5): 1–5. June 2008. doi:10.1007/s11419-007-0039-1. 
  3. "Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications". Future Medicinal Chemistry 6 (4): 385–412. March 2014. doi:10.4155/fmc.13.215. PMID 24635521. 
  4. "Studies on synthesis and relationship between analgesic activity and receptor affinity for 3-methyl fentanyl derivatives". Scientia Sinica 24 (5): 710–20. May 1981. PMID 6264594. 
  5. "[Analgesic activity and toxicity of potent analgesics, ohmefentanyl and mefentanyl]". Zhongguo Yao Li Xue Bao = Acta Pharmacologica Sinica 5 (3): 153–8. September 1984. PMID 6239505. 
  6. "Fentanyls: Are we missing the signs? Highly potent and on the rise in Europe". The International Journal on Drug Policy 26 (7): 626–31. July 2015. doi:10.1016/j.drugpo.2015.04.003. PMID 25976511. http://www.ijdp.org/article/S0955-3959%2815%2900097-3/abstract.